FLGT News and Press, Fulgent Genetics Inc. From 08/09/21

Revenue grows 790% year over year to $153.6 million Core Revenue grows 296% year over year to $25.7 million Announces acquisition of CSI Laboratories Announces commercial agreement with Helio Health through strategic investment Announces incremental controlling investm...

Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in onco...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it has acquired CSI La...

ACM, AMC, APPS, ATCO, CABO, CBT, CCXI, CF, CHGG, CMBM, CMP, COMP, CXW, DDD, DHT, DOOR, ELY, ESE, ETH, EVBG, FGEN, FLGT, HALO, HBM, HLIO, INO ,IPAR, MESA, MODN, NCMI, NHI, NTR, OSH, PEN, PLNT, PRPL, QLYS, RCKT, REAL, RETA, RGNX, RPAY, SAIL, SDC, STE, TPTX, VUZI, WES, ZIOP For Seeking Alpha's f...

With the COVID-19 pandemic, Fulgent Genetics is currently making most of its revenue from the sale of large-scale COVID-19 testing services. If the world faces new variants of the COVID-19, I assumed revenue of $927-$1,234 million. The implied share price is equal to $167-$455. Th...

Fulgent Genetics gains have been spectacular since the company entered the COVID testing market - the stock is up >250% over past 12 months. Revenues of $421m in FY20 were almost entirely due to the sale of COVID test kits. In FY19, Fulgent earned just $32m. The company is fore...

In the headline and first paragraph, first sentence of release, the date should read: Monday, August 9, 2021 (instead of Thursday, August 5, 2021). The updated release reads: FULGENT GENETICS TO ANNOUNCE SECOND QUARTER 2021 FINANCIAL RESULTS ON MONDAY, AUGUST 9, 2021 Ful...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its second quarter 2021 financial result...

Shares of Fulgent Genetics (NASDAQ: FLGT) climbed 77% through the first half of 2021, according to data from S&P Global Market Intelligence . The rise was due to the incredible numbers of COVID tests the company was able to run and the customers it was able to line up. ...

During the COVID-19 pandemic, Fulgent Genetics (NASDAQ: FLGT) was in the right place at the right time . Fulgent became a key provider of COVID-19 testing in 2020 and saw its revenue explode by almost 1,300% over the prior year. Few companies benefited more during the pandem...